NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is ...

NICE is unable to make a recommendation about the use in the NHS of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

The first patient with small cell lung cancer has been dosed in a trial of peluntamig ... to evaluate peluntamig in combination with the anti-PD-L1 therapy Tecentriq (atezolizumab). Dose-limiting ...

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma. Among these ...

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Patients with HCC at high risk of recurrence after resection or local ablation were randomly assigned to receive either atezolizumab plus bevacizumab ... or late recurrence (de novo cancer), which ...

Moving Tagrisso into the adjuvant setting in early lung cancer, adding to its use as ... Roche has approval for its PD-L1 inhibitor Tecentriq (atezolizumab) after surgery and platinum-based ...

“We are committed to addressing the remaining unmet need in lung cancer through our broad development ... as is Roche’s Tecentriq (atezolizumab), with a similar indication, but in tumours ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...